Epidemiology of major neurodegenerative diseases in women: Contribution of the nurses' health study

American Journal of Public Health

Volumn 106, Issue 9, 2016, Pages 1650-1655

  Hagan, Kaitlin A ^a   Munger, Kassandra L ^b   Ascherio, Alberto ^a,b   Grodstein, Francine ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; EPIDEMIOLOGY; FEMALE; HUMAN; LONGITUDINAL STUDY; MIDDLE AGED; NEURODEGENERATIVE DISEASES; NURSE; PROSPECTIVE STUDY; RISK FACTOR; UNITED STATES; WOMEN'S HEALTH;

ADULT; EPIDEMIOLOGIC STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NEURODEGENERATIVE DISEASES; NURSES; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; WOMEN'S HEALTH;

EID: 84982152417     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2016.303324     Document Type: Review

References (45)

1. Alzheimer's Association. 2015 Alzheimer's disease facts and figures. Alzheimers Dement. 2015;11(3):332-384.
2. Brandt J, Welsh KA, Breitner JC, Folstein MF, Helms M, Christian JC. Hereditary influences on cognitive functioning in older men: A study of 4000 twin pairs. Arch Neurol. 1993;50(6):599-603.
3. Albert M, Smith LA, Scherr PA, Taylor JO, Evans DA, Funkenstein HH. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int JNeurosci. 1991;57(3-4):167-178.
4. Morris JC, Edland S, Clark C, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part IV: Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993;43(12):2457-2465.
5. Evans DA, Grodstein F, Loewenstein D, Kaye J, Weintraub S. Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment-part 2. Alzheimers Dement. 2011; 7(1):110-123.
6. Moneim AE. Oxidant/Antioxidant imbalance and the risk of Alzheimer's disease. Curr Alzheimer Res. 2015; 12(4):335-349.
7. Devore EE, Kang JH, Stampfer MJ, Grodstein F. The association of antioxidants and cognition in the Nurses' Health Study. Am J Epidemiol. 2013;177(1):33-41.
8. Devore EE, Kang JH, Stampfer MJ, Grodstein F. Total antioxidant capacity of diet in relation to cognitive function and decline. Am J Clin Nutr. 2010;92(5): 1157-1164.
9. Devore EE, Kang JH, Breteler MM, Grodstein F. Dietary intakes of berries and flavonoids in relation to cognitive decline. Ann Neurol. 2012;72(1):135-143.
10. Grosso G, Estruch R. Nut consumption and age-related disease. Maturitas. 2016;84:11-16.
11. O'Brien J, Okereke O, Devore E, Rosner B, Breteler M, Grodstein F. Long- Term intake of nuts in relation to cognitive function in older women. J Nutr Health Aging. 2014;18(5):496-502.
12. Jacobs DR Jr, Tapsell LC. What an anticardiovascular diet should be in 2015. Curr Opin Lipidol. 2015;26(4): 270-275.
13. Samieri C, Okereke OIE Devore E, Grodstein F, Long- Term adherence to the Mediterranean diet is associated with overall cognitive status, but not cognitive decline, in women. J Nutr. 2013;143(4):493-499.
14. Stampfer MJ, Kang JH, Chen J, Cherry R, Grodstein F. Effects of moderate alcohol consumption on cognitive function in women. N Engl JMed. 2005;352(3):245-253.
15. Martínez-Lapiscina EH, Clavero P, Toledo E, et al. Virgin olive oil supplementation and long- Term cognition: The PREDIMED-NAVARRA randomized, trial. J Nutr Health Aging. 2013;17(6):544-552.
16. Martínez-Lapiscina EH, Clavero P, Toledo E, et al. Mediterranean diet improves cognition: The PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry. 2013;84(12):1318-1325.
17. Carvalho A, Rea IM, Parimon T, Cusack BJ. Physical activity and cognitive function in individuals over 60 years of age: A systematic review. Clin Interv Aging. 2014;9: 661-682.
18. Weuve J, Kang JH, Manson JE, Breteler MM, Ware JH, Grodstein F. Physical activity, including walking, and cognitive function in older women. JAMA. 2004; 292(12):1454-1461.
19. Fillit HM. The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch Intern Med. 2002;162(17):1934-1942.
20. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012;19(3): 257-271.
21. Kang JH, Grodstein F. Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol Aging. 2012;33(7):1129-1137.
22. Kang JH, Logroscino G, De Vivo I, Hunter D, Grodstein F. Apolipoprotein E, cardiovascular disease and cognitive function in aging women. Neurobiol Aging. 2005;26(4):475-484.
23. Okereke OI, Xia W, Selkoe DJ, Grodstein F. Tenyear change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol. 2009;66(10):1247-1253.
24. Logroscino G, Kang JH, Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ. 2004;328(7439):548.
25. Okereke OI, Pollak MN, Hu FB, Hankinson SE, Selkoe DJ, Grodstein F. Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. Psychoneuroendocrinology. 2008; 33(4):455-461.
26. Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: Race, sex, and geography. Ann Neurol. 2004;55(1): 65-71.
27. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: A metaanalysis. Ann Neurol. 2006;59(3):499-503.
28. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis, part I: The role of infection. Ann Neurol. 2007;61(4):288-299.
29. Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol. 2010;67(6):824-830.
30. Munger KL, Levin LI, O'Reilly EJ, Falk KI, Ascherio A. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: A prospective study among United States military personnel. Mult Scler. 2011;17(10): 1185-1193.
31. Ascherio A, Munger KL, Lunemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol. 2012;8(11):602-612.
32. Antonovsky A, Leibowitz U, Smith HA, et al. Epidemiologic study of multiple sclerosis in Israel. Arch Neurol. 1965;13:183-193.
33. Goldberg P. Multiple sclerosis: vitamin Dand calcium as environmental determinants of prevalence. (A viewpoint) part 2: biochemical and genetic factors. Int J Environ Stud. 1974;6(2-3):121-129.
34. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832-2838.
35. Salzer J, Hallmans G, Nystrom M, Stenlund H, Wadell G, Sundstrom P. Vitamin D as a protective factor in multiple sclerosis. Neurology. 2012;79(21):2140-2145.
36. Pereira-Santos M, Costa PR, Assis AM, Santos CA, Santos DB. Obesity and vitaminDdeficiency: A systematic review and meta- Analysis. Obes Rev. 2015;16(4):341-349.
37. Munger KL, Bentzen J, Laursen B, et al. Childhood body mass index and multiple sclerosis risk: A long- Term cohort study. Mult Scler. 2013;19(10):1323-1329.
38. Hedström AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler. 2012;18(9):1334-1336.
39. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease-false association or etiologic clue. Neurology. 1995; 45:1041-1051.
40. Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: A randomized clinical trial. JAMA Neurol. 2014;71(2): 141-150.
41. Wang H, O'Reilly EJ, Weisskopf MG, et al. Smoking and risk of amyotrophic lateral sclerosis: A pooled analysis of 5 prospective cohorts. Arch Neurol. 2011;68(2): 207-213.
42. O'Reilly EJ, Wang H, Weisskopf MG, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):205-211.
43. Wang H, O'Reilly EJ, Weisskopf MG, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis: A pooled analysis of data from 5 prospective cohort studies. Am J Epidemiol. 2011;173(6):595-602.
44. Fitzgerald KC, O'Reilly EJ, Fondell E, et al. Intakes of vitamin C and carotenoids and risk of amyotrophic lateral sclerosis: pooled results from 5 cohorts. Ann Neurol. 2013; 73(2):236-245.
45. Fitzgerald KC, O'Reilly EJ, Falcone GJ, et al. Dietary w-3 polyunsaturated fatty acid intake and risk of amyotrophic lateral sclerosis. JAMA Neurol. 2014;71(9): 1102-1110.